Listing of Claims

This listing of claims replaces all prior versions and listings of claims in the application:

Claims 1 – 10 (Canceled)

11. (Currently Amended) A compound of formula (I)



(I)

wherein:

A represents a group of formula ~~(a) or~~ (b) or (c):



(a) (b) (c) .

R^1 and R^2 independently represent H, C1 to 8 alkyl, ~~C2 to 8 alkenyl, C2 to 8 alkynyl~~ or C3 to 7 saturated or partially unsaturated cycloalkyl; the latter ~~four~~ two groups being optionally further substituted by one or more groups selected independently from OH, C1 to 6 alkoxy, CH_2OR^4, NR^5R^6, CO_2R^7 and $CONR^8R^9$;

R^3 represents C1 to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or alkynyl chain optionally including a O, NR^{10} or S atom in the chain; said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by phenyl or a 5 or 6 membered heteroaromatic ring containing 1 to 3 heteroatoms selected independently from O, S and N; said phenyl or heteroaromatic ring being optionally further substituted by one or more groups selected independently from halogen, C1 to 4 alkyl, OH, C1 to 4 alkoxy, CN, ~~$CO2R^{11}$~~ CO_2R^{11}, $NR^{12}R^{13}$, $CONR^{14}R^{15}$, SO_2R^{16}, $NR^{17}SO_2R^{18}$ and $SO_2NR^{19}R^{20}$;

X represents O or S(O);

~~R^{21} represents H, CH_2OR^{24}, $CH_2NR^{24}R^{25}$, CO_2R^{24} or $CONR^{24}R^{25}$;~~

R^{22} and R^{23} are H ~~independently represent H, C1 to 6 alkyl, C2 to 6 alkenyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or cycloalkyl group being optionally substituted by OR^{24}, $NR^{24}R^{25}$, CO_2R^{24} or $CONR^{24}R^{25}$; or the group $NR^{22}R^{23}$ together represents a 3 to 7 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, $S(O)_n$ and NR^{26}; and optionally substituted by OR^{24}, $NR^{24}R^{25}$, CO_2R^{24} or $CONR^{24}R^{25}$~~;

n represents an integer 0, 1 or 2;

R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{24}, R^{25} and R^{26} independently represent H or C1 to 6 alkyl;

and pharmaceutically acceptable salts thereof.

12. (previously presented) A compound according to Claim 11 wherein R^1 represents H or CH_3.

13. (previously presented) A compound according to Claim 11 wherein R^2 represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH_2OR^4.

14. (Currently Amended) A compound according to Claim 11 wherein R^3 represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, ~~C1 to 6~~ C1 to 4 alkoxy or CN.

Claim 15 (Canceled)

16. (previously presented) A pharmaceutical formulation comprising a compound of formula (I), as defined in Claim 11 or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.

17. (withdrawn) A method of treating, or reducing the risk of, a human disease or condition in which antagonism of the CX_3CR1 receptor is beneficial which comprises administering to a

person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in Claim 11, or a pharmaceutically acceptable salt thereof.

18. (canceled)

19. (currently amended) A method ~~The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament~~ for the treatment or prophylaxis of a disease or disorder selected from neurodegenerative disorders, demyelinating disease, atherosclerosis ~~or~~ and pain comprising administering to a patient in need thereof, a therapeutically effective amount of a compound of formula (I), as defined in Claim 11, or a pharmaceutically acceptable salt thereof.

20. (withdrawn) A process for the preparation of a compound of formula (I), as defined in Claim 11 or a pharmaceutically acceptable salt thereof, wherein the process comprises:

(a) when X in formula (I) represents O, reaction of a compound of formula (II)



(II)

wherein A, R^1, R^2 and R^3 are as defined in Claim 11;

with a compound of formula (III)



(III)

wherein R^3 is as defined in Claim 11 and is independent of the R^3 group in formula (II); or

(b) when X in formula (I) represents S(O), oxidation of a compound of formula (IV)



(IV)

wherein A, R^1, R^2 and R^3 are as defined in Claim 11; with one equivalent of an oxidising agent; and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

21. (New) A compound selected from:
(2*R*)-2-{[2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino}-4-methylpentan-1-ol;
(2*R*)-2-({2-Amino-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}amino)-4-methylpentan-1-ol;
(2*R*)-2-{[2-Amino-5-(2-phenylethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino}-4-methylpentan-1-ol;
(2*R*)-2-{[2-Amino-5-(2-phenoxyethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino}-4-methylpentan-1-ol;
(2*R*)-2-[{2-Amino-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}(methyl)amino]-4-methylpentan-1-ol;
(2*R*)-2-[{2-Amino-5-[(4-chlorobenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}(methyl)amino]-4-methylpentan-1-ol;
(2*R*)-2-[{2-Amino-5-[(3-chlorobenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}(methyl)amino]-4-methylpentan-1-ol;
(2*R*)-2-[{2-amino-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}(methyl)amino]-4-methylpentan-1-ol;
(2*R*)-2-[[2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol;
(2*R*)-[{2-Amino-5-[(4-bromo-2-fluorobenzyl)-(R_S,S_S)-sulfinyl][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}(methyl)amino]-4-methylpentan-1-ol;

(2*R*)-2-[(2-Amino-5-{[2-(4-bromophenyl)ethyl]-(R_S,S_S)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-4-methylpentan-1-ol;

(2*R*)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-(R_S,S_S)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-4-methylpentan-1-ol;

(*R*)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-(R_S,S_S)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol;

5-(Benzyloxy)-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-5-(2-phenylethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-(Benzyloxy)-7-{[(1*R*)-1-(hydroxymethyl)butyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[(1*R*)-1-(Hydroxymethyl)butyl]amino}-5-{[(1*S*)-1-phenylethyl]oxy}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

N-(3-{[(7-{[(1*R*)-1-(Hydroxymethyl)butyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl}phenyl)-*N*-methylmethanesulfonamide;

N-(3-{[(7-{[(1*R*)-1-(Hydroxymethyl)-2-methylpropyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl}phenyl)-methanesulfonamide;

5-(Benzyloxy)-7-{[1-(hydroxymethyl)cyclopentyl]amino}-[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(3-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(2-Chlorobenzyl)oxy]-7-{[1-(hydroxymethyl)cyclopentyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(3-Chlorobenzyl)oxy]-7-{[1-(hydroxymethyl)cyclopentyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(4-Chlorobenzyl)oxy]-7-{[1-(hydroxymethyl)cyclopentyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

4-{[(7-{[1-(Hydroxymethyl)cyclopentyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl}benzonitrile;

(*R*,*S*)-7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-(1-phenylethoxy)-thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-{[1-(Hydroxymethyl)cyclopentyl]amino}-5-{[(1*S*)-1-phenylethyl]oxy}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-{[2-(3-Chlorophenyl)-(R_S,S_S)-ethyl]sulfinyl}-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-{[2-(2-Bromophenyl)ethyl]-(R_S,S_S)-sulfinyl}-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(2,3-Difluorobenzyl)-(R_S,S_S)-sulfinyl]-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[Benzyl-(R_S,S_S)-sulfinyl]-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(2-Chlorobenzyl)-(R_S,S_S)-sulfinyl]-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(4-Chlorobenzyl)-(R_S,S_S)-sulfinyl]-7-{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[Benzyl-(R_S,S_S)-sulfinyl]-7-{[(1*R*)-1-(hydroxymethyl)-2-methylpropyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one; a pharmaceutically acceptable salt thereof, and mixtures thereof.

22. (new) A pharmaceutical formulation comprising a compound in accordance with claim 21 optionally in admixture with a pharmaceutically acceptable diluent or carrier.